





*Article*


# **Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial-Mesenchymal Transition**

**Karina Martins-Cardoso, Vitor H. Almeida, Kayo M. Bagri, Maria Isabel Doria Rossi, Claudia S. Mermelstein, Sandra König and Robson Q. Monteiro**


**Supplementary Materials**









**Figure S1.** Uncropped blots for analysis of EMT markers. MCF7 cells were starved and treated with NETs for 3 to 24 hours. MDA-MB-231 cells (MDA) were used as a mesenchymal cell model. The figure shows the uncropped blots revealed with antibodies against (a) E-cadherin, (b) fibronectin, (c) vimentin, or (d)  $\beta$ -actin, which was used as the loading control. Also, (e) E-cadherin levels were analyzed in HCC 1954 cells treated with NETs, using  $\beta$ -actin as a loading control. Densitometric analysis was performed with the ImageJ software (NIH, USA). Fold difference was calculated in relation to untreated MCF7 cell line (a,b), MDA-MB-231 cells (c), or untreated HCC 1954 cells (e) depicted at the bottom of each blot. Molecular weight was determined using the Novex™ Sharp Pre-stained Protein Standard (#LC5800, ThermoFisher Scientific). Experiment #1 and experiment #2 refer to two independent assays.



**Figure S2.** Effect of NETs on HER2+ breast cancer cells. HCC 1954 cells were treated with NETs (500 ng/mL) for 16 h (gene expression analyzes) or 24h (western blot). (a) Gene expression of *MMP9* and E-cadherin (*CDH1*) was evaluated by quantitative RT-PCR using the  $\Delta\Delta CT$  method. *GAPDH* was used as the reference gene. Columns represent means  $\pm$  SD of three independent experiments. \*\* denotes  $p < 0.01$  (unpaired *t*-test). (b) Protein levels of E-cadherin and  $\beta$ -actin (loading control) were evaluated by western blotting.



**Figure S3.** Quantitative analysis of immunocytochemistry assays for EMT markers in NETs-treated MCF7 cells. Quantification of the immunostaining shown in the Figures 2c–f was performed using the ImageJ software. The unpaired *t*-test was applied as a statistical method. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .



**Figure S4.** The pro-tumoral effects of NETs are independent of DNA integrity. (a) The digestion of NETs was evaluated by agarose gel electrophoresis. NETs, prepared from two distinct healthy donors, were incubated with 5 U DNase I (Pulmozyme®, Roche, Basel, Switzerland), at 37 °C, for the indicated times. (b) Tumor cell migration was evaluated employing the Boyden chamber assay. MCF7 cells that were cultured for 16 h in the absence or the presence of either full or digested (5 U DNase I, 30 min, 37 °C) NETs (500 ng/mL) were seeded in the upper chamber ( $5 \times 10^4$  cells/well) and further allowed to migrate for 20 h. As chemoattractant, medium supplemented with FBS (2% or 10%) was used in lower chambers. Data are presented as mean  $\pm$  SD from three independent experiments. Statistical analysis of each condition was evaluated by unpaired *t*-test. \*  $p < 0.05$ , *n.s.*, no significance. (c,d) MCF7 cells were treated for 16 h with either full or digested NETs (500 ng/mL). Gene expression of IL-8 (*CXCL8*) and *MMP9* was evaluated by quantitative RT-PCR using the  $\Delta\Delta$ CT method. *GAPDH* was used as the reference gene. Columns represent means  $\pm$  SD of three independent experiments. Statistical analysis was performed using one-way ANOVA and Tukey post-test. \*  $p < 0.05$ , \*\*  $p < 0.01$ , *n.s.*, no significance.

Table S1. qRT-PCR primer sequences.

<b>Primer</b>	<b>Forward primers (5'–3')</b>	<b>Reverse primers (5'–3')</b>	<b>Size bp</b>
<i>GAPDH</i>	5'- TGCACCACCAACTGCTTAGG -3'	5'- GGCATGGACTGTGGTCATGAG -3'	87
<i>CXCR1</i>	5'- CGTCTGTCAATGTCTCTTCCAACC -3'	5'- GATAGTGCCTGTCCAGAGCCAG -3'	127
<i>IL1B</i>	5'- GGACAGGATATGGAGCAACAA -3'	5'- TCTTTCAACACGCAGGACAG -3'	128
<i>IL6</i>	5'- TACCCCAGGAGAAGATTCC -3'	5'- TTTTCTGCCAGTGCCTCTTT -3'	174
<i>CXCL8</i>	5'- CTGGACCCCAAGGAAAACCTG -3'	5'- GAATTCTCAGCCCTCTTCAAAAAC -3'	65
<i>MMP2</i>	5'- AGCTCCCGGAAAGAGTTGATG -3'	5'- CAGGGTGCTGGCTGAGTAGAT -3'	101
<i>MMP9</i>	5'- GCAATGCTGATGGGAAACCC -3'	5'- AGAAGCCGAAGAGCTTGTCC -3'	144
<i>TWIST1</i>	5'- CCGGAGACCTAGATGTCATT -3'	5'- CACGCCCTGTTTCTTTGAA -3'	148
<i>SNAI1</i>	5'- TCG GAA GCC TAA CTA CAG CGA -3'	5'- AGA TGA GCA TTG GCA GCG AG -3'	140
<i>SNAI2</i>	5'- AAG CAT TTC AAC GCC TCC AAA -3'	5'- GGA TCT CTG GTT GTG GTA TGA CA -3'	118
<i>ZEB1</i>	5'- TGGAATGTATGCTTGTGATTTGTG -3'	5'- GAATAAGACCCAGAGTGTGAGAAG -3'	225
<i>ZEB2</i>	5'- CCC TTC TGC GAC ATA AAT ACG A -3'	5'-TGT GAT TCA TGT GCT GCG AGT -3'	192
<i>CD24</i>	5'- CCCACGCAGATTTATTCCAG -3'	5'- GACTTCCAGACGCCATTTG -3'	255
<i>CD44</i>	5'- GGAGCAGCACTTCAGGAGGTTAC -3'	5'- GGAATGTGTCTTGGTCTCTGGTAGC -3'	129
<i>PTGS2</i>	5'- TGGTGCCTGGTCTGATGATG -3'	5'- GCCTGCTTGTCTGGAACAAC -3'	120